EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV
EUS-guided interventions: General Aspects and EUS-guided Sampling (short version)

EFSUMB Leitlinien interventioneller Ultraschall (INVUS), Teil IV
Endosonografisch gestützte Interventionen: allgemeine Aspekte und endosonografisch gestützte Materialgewinnung (Kurzversion)

Authors
C. Jenssen1, M. Hocke2, P. Fusaroli3, O. H. Gilja4, E. Buscarini5, R. F. Havre6, A. Ignee7, A. Saftoiu8, P. Vilmann9, C. F. Dietrich16, 17

Affiliations
Affiliation addresses are listed at the end of the article.

Key words
- guideline
- endoscopic ultrasound
- EUS-guided sampling
- EUS-guided fine-needle aspiration
- rapid onsite cytopathological evaluation
- cytopathological reporting
- quality indicators
- adverse events

Abstract
The fourth part of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines on Interventional Ultrasound describes general aspects of endoscopic ultrasound-guided diagnostic and therapeutic interventions and assesses the evidence for endoscopic ultrasound-guided sampling. Endoscopic ultrasound combines the most advanced high-resolution ultrasound imaging of lesions within the wall and in the vicinity of the gastrointestinal tract and safe and effective fine needle-based tissue acquisition from these lesions. The guideline addresses the indications, contraindications, techniques, adverse events, training and clinical impact of EUS-guided sampling. Advantages and drawbacks are weighed in comparison with image-guided percutaneous biopsy. Based on the most current evidence, clinical practice recommendations are given for crucial preconditions and steps of EUS-guided sampling as well as for safe performance. Additionally, the guideline deals with the principles and reliability of cytopathological reporting in endoscopic ultrasound-guided sampling (short version; the long version is published online).

Introduction: Diagnostic and therapeutic EUS-guided interventions
This is the first of two guidelines (parts IV and V) within the framework of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines on Interventional Ultrasound describing endoscopic ultrasound (EUS)-guided diagnostic and therapeutic interventions.

Part IV deals with the indications and clinical impact of EUS-guided sampling1 and gives evidence-based recommendations for the safe and efficient performance of this technique based on the available evidence at the time of manuscript prepara-

1 Term is explained in the addendum on terminology (online version only).
Endoscopic ultrasound (EUS; synonym: endosonography) represents an interdisciplinary high-performance imaging method which combines endoscopy and ultrasound by using special transducers mounted at the tip of the endoscope [3 – 9]. With the introduction of EUS-guided fine-needle aspiration (EUS-FNA) in 1992 [10], it became possible to obtain a definitive cytopathological or histopathological diagnosis of mediastinal, abdominal, retroperitoneal and pelvic lesions, establishing EUS-FNA as a crucial procedure. Further advances in 1996, allowed EUS-guided celiac plexus neurolysis [11], EUS-guided drainage of GI tract-adjacent fluid collections and pancreatic pseudocysts [12]. A first experience with endobronchial ultrasound-guided transbronchial fine-needle aspiration (EBUS-TBNA) was reported in 2003 [13].

Platforms for EUS-guided diagnostic and therapeutic interventions

Needles for EUS-guided sampling are available with a size of 25 – 19 Gauge (G) [14, 15, 47 – 49]. “Histology needles” include: trucut needles, needles with side fenestration and reverse bevel technology [50 – 57] or with shark mouth-like needle tip geometry. Therapeutic EUS-guided interventions commence with puncture of the targeted lesion for initial access, followed by therapeutic injection or a guidewire-assisted drainage procedure. 19 G needles are normally used, allowing passage of 0.035 inch guidewires.

Indications and contraindications

EUS has evolved as a diagnostic and therapeutic procedure with substantial clinical impact, altering management in a number of patients [3, 29, 57 – 63]. Appropriate (evidence-based) indications are listed in Table 1 [3, 7 – 9, 29, 57, 64 – 69]. Absolute contraindications of EUS are similar with those of conventional advanced endoscopy procedures. Specific contraindications of EUS-guided sampling and therapeutic interventions are related to unacceptable risks of bleeding, infection, and perforation (Table 2; section 5) [8, 9, 14, 66, 70, 71], which should be assessed prior to the intervention on an individual basis weighing procedural risk vs. clinical impact.

Recommendation 3

Carefully monitored conscious or deep sedation should be routinely offered to all patients undergoing EUS-guided interventions (LoE 1b, GoR B). Strong consensus (100%).

Recommendation 4

Controlled propofol sedation should be used with due consideration of national legal regulations, and experience and training of the medical personnel (LoE 5, GoR D). Strong consensus (100%).

2 Term is explained in the addendum on terminology (online version only).
3 Term is explained in the addendum on terminology (online version only).
4 Term is explained in the addendum on terminology (online version only).
Table 1  Established indications of endoscopic ultrasound.

<table>
<thead>
<tr>
<th>diagnostic evaluation (including EUS-guided sampling)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pancreatico-biliary disorders</td>
</tr>
<tr>
<td>obstructive jaundice/biliary stricture</td>
</tr>
<tr>
<td>of unknown aetiology</td>
</tr>
<tr>
<td>suspected bile duct stones</td>
</tr>
<tr>
<td>biliary and idiopathic acute pancreatitis</td>
</tr>
<tr>
<td>(early) chronic pancreatitis</td>
</tr>
<tr>
<td>solid and cystic focal pancreatic lesions</td>
</tr>
<tr>
<td>oesophagogastro-duodenal tumours</td>
</tr>
<tr>
<td>subepithelial tumours</td>
</tr>
<tr>
<td>enlarged gastric folds/wall thickening</td>
</tr>
<tr>
<td>mediastinal diseases</td>
</tr>
<tr>
<td>primary central lung/mediastinal tumours</td>
</tr>
<tr>
<td>mediastinal lymphadenopathy</td>
</tr>
<tr>
<td>rectal diseases</td>
</tr>
<tr>
<td>fistulas, abscesses, extraluminal tumours,</td>
</tr>
<tr>
<td>subepithelial tumours</td>
</tr>
<tr>
<td>staging of various cancers</td>
</tr>
<tr>
<td>upper gastrointestinal cancer</td>
</tr>
<tr>
<td>T (tumour) and N (nodal) stage, M (metastatic) stage</td>
</tr>
<tr>
<td>(celiac trunk lymph nodes, left adrenal, left liver lobe, ascites, etc.)</td>
</tr>
<tr>
<td>lung cancer</td>
</tr>
<tr>
<td>T and N stage (EUS and EBUS), M stage</td>
</tr>
<tr>
<td>(abdominal lymph nodes, left adrenal, left liver lobe)</td>
</tr>
<tr>
<td>rectal cancer</td>
</tr>
<tr>
<td>T and N stage</td>
</tr>
<tr>
<td>pancreatico-biliary cancers</td>
</tr>
<tr>
<td>T and N stage, M stage (left liver lobe, ascites,</td>
</tr>
<tr>
<td>mediastinal lymph nodes, etc.), evaluation of</td>
</tr>
<tr>
<td>resectability and vascular invasion</td>
</tr>
<tr>
<td>EUS-guided therapeutic interventions</td>
</tr>
<tr>
<td>drainage procedures</td>
</tr>
<tr>
<td>transmural drainage of (per-) pancreatic and</td>
</tr>
<tr>
<td>peri-intestinal fluid collections (pseudocysts,</td>
</tr>
<tr>
<td>walled-off pancreatic necroses, abscesses,</td>
</tr>
<tr>
<td>postoperative fluid collections)</td>
</tr>
<tr>
<td>bile duct and gallbladder drainage</td>
</tr>
<tr>
<td>pancreatic duct drainage</td>
</tr>
<tr>
<td>injection treatment</td>
</tr>
<tr>
<td>celiac plexus/ganglia neurolysis and block</td>
</tr>
<tr>
<td>glue or coil embolization of bleeding varices, visceral</td>
</tr>
<tr>
<td>pseudoaneurysms, and other vascular lesions</td>
</tr>
<tr>
<td>ethanol ablation of small pancreatic insulinosomas</td>
</tr>
<tr>
<td>other interventions</td>
</tr>
<tr>
<td>placement of fiducials</td>
</tr>
</tbody>
</table>

Table 2  Indications and contraindications of EUS-guided sampling.

<table>
<thead>
<tr>
<th>frequent/established indications</th>
<th>less frequent/ emerging indications</th>
<th>contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>pancreatic solid lesions</td>
<td>retroperitoneal masses</td>
<td>absolute</td>
</tr>
<tr>
<td>pancreatic cystic lesions</td>
<td>mediastinal masses</td>
<td>no impact on patient management</td>
</tr>
<tr>
<td>lymph nodes</td>
<td>perianastomotic masses</td>
<td>lack of informed consent</td>
</tr>
<tr>
<td>subepithelial tumours</td>
<td>adrenal gland masses</td>
<td>mediastinal cysts (risk of infection)</td>
</tr>
<tr>
<td>liver masses</td>
<td></td>
<td>relative</td>
</tr>
<tr>
<td>ascites and peritoneal nodules</td>
<td></td>
<td>severe coagulopathy</td>
</tr>
<tr>
<td>gastrointestinal wall thickening</td>
<td></td>
<td>continued oral anticoagulation</td>
</tr>
<tr>
<td>bile duct strictures/lesions</td>
<td></td>
<td>continued treatment with ADP antagonists (clopidogrel, prasugrel, ticagrelor)</td>
</tr>
<tr>
<td>kidney masses</td>
<td></td>
<td>large vessels in the expected needle track</td>
</tr>
<tr>
<td>focal splenic lesions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Recommendation 5

As EUS is an advanced invasive procedure, it requires a proper indication, assessment of individual risks and contraindications, detailed informed consent, considerate management of antithrombotic therapy and antibiotic prophylaxis, and a pre-interventional team time-out\(^5\) (LoE 5, GoR D). Strong consensus (100%).

Education and training in endoscopic ultrasound

Preconditions for performing EUS

EUS has evolved into an advanced endoscopic procedure requiring structured training as supported by the ASGE core curriculum for EUS [72]. Certain conditions need to be attained prior to commencing an EUS program; state-of-the-art EUS equipment and accessories should be in place, previous EUS experience and training (>12 months) with proficiency in basic EUS should be available, the presence of a multidisciplinary team with expertise in gastroenterology, pulmonary medicine, oncology, surgery, imaging and pathology is desired.

Methods and models for training

Various approaches for structured training have been described. Support includes EUS textbooks and atlases, DVDs and online resources [7 – 9, 73 – 78]. Computer-based simulator training, EUS-guided sampling and therapeutic intervention training with animal models and supervised hands-on may facilitate improved learning for clinical application and may minimize false-negative sampling in patients [73, 76, 79 – 93]. Objective assessment tools with rating scales for various steps of EUS-guided sampling have been developed to measure competency for mediastinal staging of NSCLC [83, 85, 90, 91, 94 – 96].

Learning curve and minimum number of supervised procedures

Reports on the skill acquisition of individuals for EUS [97, 98] and for EUS-FNA of solid pancreatic lesions [99, 100] challenge the ASGE recommendations that comprehensive competence in all aspects of EUS requires at least 150 supervised cases, including 50 EUS-FNA [101]. Also for EBUS-TBNA, studies show significant variation in learning curves [96] with an acceptable 90% accuracy achieved after performing 50 – 80 procedures [102 – 105].

Recommendation 6

Education and training for EUS procedures should be performed systematically in a standardized fashion. Various learning methods should be used, including textbooks and on-line resources, and EUS phantoms, before performing hands-on human cases (LoE 5, GoR D). Strong consensus (100%).

Recommendation 7

Standardized criteria and assessment tools should be developed and applied for assessing skills of individual trainees before credentialing competency (LoE 1b, GoR B). Strong consensus (100%).

---

\(^5\) Term is explained in the addendum on terminology (online version only).

Recommendation 8
At least 50 EUS-guided sampling procedures are needed in order to attain basic competency in EUS-guided interventions (LoE 5, GoR D). Strong consensus (100%).

Quality indicators and benchmarking
Useful quality indicators for EUS-guided sampling may be:

a) percentage of appropriate indications for performing EUS-guided sampling due to guidelines (Table 2) [29]
b) prospective documentation of adverse events after EUS-guided sampling (performance target: > 98%) [29]
c) incidence of adverse events after EUS-guided sampling (performance targets: acute pancreatitis < 2%, clinically significant bleeding < 1%) [29, 48, 66]
d) frequency of algorithmic EUS-guided sampling of both suspected metastatic disease and the primary tumour in cases, in which results of EUS staging would impact further clinical management (performance target: > 98%) [29]
e) the yield of malignant diagnoses in EUS-guided sampling of solid pancreatic masses and the sensitivity for diagnosis of pancreatic cancer (performance targets: ≥ 70 and 85%, respectively) [29, 48, 57, 66, 106]
f) the percentage of adequate samples (performance target: ≥ 85%) [29, 48, 66] and
g) the frequency of inconclusive cytopathological diagnoses (atypical, suspicious: ≤ 10%) [48, 66, 107].

Particular quality parameters for EUS-guided therapeutic interventions have not as yet been established, but should be derived from those for EUS-guided sampling and advanced endoscopic and interventional procedures [29, 108].

Recommendation 9
Appropriate indicators should be implemented to monitor the quality of EUS-guided interventions (LoE 5, GoR D). Strong consensus (100%).

EUS-guided sampling: Indications and clinical impact

General indications of EUS-guided sampling
EUS has high accuracy for the diagnosis and staging of benign and malignant conditions within and outside the gastrointestinal tract (Table 2) [61, 62]. EUS-guided sampling relies on its ability to obtain specimens with either fine-needle aspiration (FNA) or fine-needle biopsy (FNB) [57, 66].

Several prospective and retrospective studies and meta-analyses have substantiated the key importance of EUS-guided sampling particularly in suspicious nodal disease for staging, guiding treatment, and predicting outcome in non-small cell lung cancer (NSCLC) [109–114], various extrathoracic malignancies [115, 116], upper gastrointestinal cancer [117, 118], rectal cancer [23], as well as proving recurrence of malignancy [20, 119–122]. Specimens provided by EUS can be examined by immunohistochemical and biological marker analysis to identify specific tumour characteristics, facilitating personalized treatment [123–131].

Recommendation 10
EUS-guided sampling should be considered for tissue diagnosis of lesions in or adjacent to the gastrointestinal tract where the result is likely to alter clinical management (LoE 2a, GoR B). Strong consensus (100%).

EUS-guided sampling for primary diagnosis
Pancreatic solid lesions
Solid pancreatic lesions suspected as ductal pancreatic adenocarcinoma (PDAC) are typically targets for EUS-guided sampling. Metastases and/or primary lesion sampling is indicated when the lesion is non-resectable allowing appropriate radiotherapy/chemotherapy. EUS-guided sampling of potentially resectable tumours will follow local protocols to obtain confirmation of malignancy prior to surgical intervention.

EUS has a high positive predictive value (PPV) and a fair negative predictive value (NPV) in diagnosing PDAC. Several studies report a sensitivity between 85–93% and a specificity between 96–100% [132–136].

EUS-guided sampling is a reliable method to differentiate PDAC from neuroendocrine pancreatic tumours and other rare pancreatic neoplasms (non-PDAC), each with differing outcomes and alternative treatment strategies [137–140].

Recommendation 11
In pancreatic masses, EUS-guided sampling should be preferred in potentially resectable lesions and in unresectable lesions in which percutaneous biopsy is not feasible (LoE 2b, GoR C). Strong consensus (100%).

Recommendation 12
EUS-guided sampling should be preferred over percutaneous biopsy in pancreatic masses prior to neoadjuvant radiotherapy/chemotherapy (LoE 2b, GoR C). Strong consensus (100%).

Recommendation 13
EUS-guided sampling is recommended in potentially resectable, pancreatic masses that are atypical for pancreatic ductal adenocarcinoma (LoE 3b, GoR C). Strong consensus (100%).

Pancreatic cystic lesions
There is a wide differential diagnosis of pancreatic cystic lesions (PCL) including both benign and malignant [141–143].

EUS-guided sampling aims to differentiate mucinous from non-mucinous and malignant from benign lesions. For best diagnostic accuracy, EUS-FNA cytology and biochemical aspirate assays should be reviewed in combination with the EUS findings, clinical history and other imaging techniques [144–146]. Levels of carcinoembryonic antigen (CEA) and amylase yield a suboptimal diagnostic accuracy of 60–86% for distinguishing between mucinous and non-mucinous PCL [147–150]. The spe-
cificity of cytological diagnosis of malignant PCL is adequate, but the sensitivity is low (88–97 % and 51–65 %, respectively) [150 – 153]. The combination of molecular analysis and CEA or cytology has a better performance for the diagnosis of neoplastic mucinous PCL than either of the individual tests [154 – 156].

Recommendation 14
Biochemical, cytological, and molecular analysis of EUS aspirates from pancreatic cystic lesions may facilitate differentiation between mucinous and non-mucinous cysts and evaluation of the malignancy risk (LoE 2a, GoR B). Strong consensus (100 %).

Biliary cancer
Several studies report successful EUS-guided sampling of gallbladder wall lesions [157 – 161], extrahepatic cholangiocarcinoma and indeterminate biliary strictures [157, 162 – 173], as well as tumours of the papilla of Vater [174], but with wide variation in sensitivity (43 – 100 %) [175]. EUS-guided sampling proved to be successful following failed or negative ERCP-guided brushing or biopsy [163, 165 – 169, 175]. Comparison of EUS-guided sampling with that of ERCP-guided techniques revealed a better outcome for EUS in gallbladder cancer, biliary strictures produced by pancreatic cancer rather than cholangiocarcinoma, and in EUS-visible masses, with a combined approach considered clinically appropriate [159, 161, 164, 173, 175]. EUS-guided sampling of hilar lymph nodes may be used to diagnose and stage suspected biliary cancer [159, 160, 162, 168, 172, 176].

Recommendation 15
Complementary to ERCP-guided brushing and biopsy, EUS-guided sampling may be used for diagnosis of indeterminate biliary strictures and gallbladder masses (LoE 2a, GoR B). Strong consensus (100 %).

Subepithelial gastrointestinal tumours
Differential diagnosis of gastrointestinal subepithelial tumours (SET) includes leiomyoma, schwannoma, gastrointestinal stromal tumour (GIST), lipoma, ectopic pancreas, neuroendocrine tumour, cyst and others [177 – 179]. Whilst a reliable differential diagnosis is possible on EUS features alone in some SETs, so, with the frequently occurring hypoechoic SET originating from the 4th layer (muscularis propria), i.e. GIST, leiomyoma and schwannoma, diagnosis may be problematic [177 – 179]. EUS-guided sampling combines smear cytology (SC) with immunohistochemistry for maximal diagnostic accuracy. The diagnostic yield remains suboptimal using standard EUS needles of various diameters, ranging from 20 [180] to 93 % [181], as retrieved tissue is not always sufficient to allow immunohistochemical analysis [181 – 195]. The European Society of Gastrointestinal Endoscopy (ESGE) guideline on EUS-guided sampling in gastroenterology states that in hypoechoic SET of the stomach <20 mm the usefulness of EUS-guided sampling is limited due to the moderate diagnostic yield and lacking capability to determine the mitotic index [59].

Recommendation 16
EUS-guided sampling may be used for differential diagnosis of subepithelial gastrointestinal tumours ≥20 mm in cases with high surgical risk or suspected non-resectability (LoE 2b, GoR C). Strong consensus (100 %).

Lung cancer
In suspected lung cancer conventional techniques (bronchoscopic or percutaneous-transsthoracic biopsy) fail to establish a histological diagnosis in up to ¼ of patients. EUS allows effective transoesophageal or transbronchial guidance for sampling of centrally located lung masses or lymph nodes adjacent to the oesophagus or the respiratory tract [196 – 203]. Subtyping of non-small cell lung cancer is the basis of personalized oncological treatment and is feasible using EUS-guided sampling in 77 – 90.6 % [204 – 206]. Genotyping was possible using EUS-/EBUS fine-needle aspirates in 77 – 98.4 % [124, 204 – 209].

Recommendation 17
In suspected lung cancer EUS-guided sampling (EUS-FNA, EBUS-TBNA) of centrally-located mass lesions or suspicious lymph nodes is recommended to establish a definite tissue diagnosis complementing other diagnostic techniques (LoE 2b, GoR B). Strong consensus (100 %).

Mediastinal and abdominal lymphadenopathy of unknown origin
For lymph node classification as malignant or benign, EUS-FNA has a higher accuracy than EUS features alone [210, 211]. A meta-analysis (n = 9310) showed significant improvement in evaluating mediastinal lymphadenopathy with EUS-guided sampling over EUS features of lymph nodes (sensitivity 88 vs. 84.7 %; specificity 96.4 vs. 84.6 %) [212]. Several studies and meta-analyses have demonstrated a high diagnostic yield and accuracy of EUS-guided sampling (EUS-FNA and EBUS-TBNA) for the evaluation of indeterminate mediastinal and abdominal lymphadenopathy, with or without a malignant disease background [114, 116, 120, 212 – 234].

Recommendation 18
EUS-guided sampling (EUS-FNA, EBUS-TBNA) is recommended as the primary diagnostic technique for tissue diagnosis of mediastinal or abdominal lymphadenopathy of unknown aetiology (LoE 3a, GoR B). Strong consensus (100 %).

EUS-guided sampling for tumour staging
Algorithmic approach
For tumour staging an algorithmic approach of EUS-guided sampling following the TNM classification of the respective malignant tumour is sensible. Potential sites of metastases within reach of EUS-FNA should be examined and sampled first, followed by regional lymph node stations, in which demonstration of metastatic involvement would alter management [76, 235 – 237]. This systematic approach in an inverse TNM order meets concerns that needle contamination with tumour cells from the first sampling target, from the instrumental channel or from gas-
trointestinal fluid could contribute to false-positive results from the subsequent targeted lesions [238–241].

**Mediastinal lymph nodes**

In the absence of distant metastases, mediastinal lymph node involvement is the most important factor affecting the management and outcome of patients with NSCLC [236]. Oesophageal EUS has a high sensitivity and specificity for lymph node involvement when found in the posterior mediastinum, aortopulmonary, subcarinal, and periesophageal regions [68, 212, 236, 242–244]. Meta-analyses report a sensitivity and specificity between 83–89 % and 96.4–100 %, respectively, for nodal staging of lung cancer by EUS-guided sampling [110–114, 225, 236, 245]. EUS has been shown to be more accurate than CT in defining the disease stage [244, 246, 247]. EUS-guided sampling impacts treatment choice and survival in patients with NSCLC [247–250]. Oesophageal EUS and EBUS in combination allow targeting of nearly all relevant mediastinal lymph node locations [251–254]. Several studies and meta-analyses have shown that this combined approach improves lymph node staging, compared with either technique when used alone [112, 114, 236, 237, 250, 255–263]. There is a 21 % sensitivity increase for mediastinal nodal staging in proven or suspected lung cancer by performing combined endobronchial and oesophageal endosonography-guided sampling compared with the oesophageal approach alone, and a 13 % increase compared with EBUS-TBNA alone [237]. Both oesophageal EUS and EBUS have also been successfully used for the assessment of tumour spread to mediastinal lymph nodes (M1 disease) in a variety of extra-thoracic malignant disease [115, 213, 220, 223, 264–268]. A meta-analysis (n = 533 patients) showed a sensitivity of 85 % and a specificity of 99 % of EBUS-TBNA for the diagnosis of mediastinal lymph node metastases of extra-thoracic malignancies [116]. EUS-FNA of mediastinal lymph nodes for the N staging of oesophageal cancer is more sensitive and accurate than EUS alone and significantly impacts therapeutic decisions [269–271].

**Abdominal lymph nodes**

Previous studies have shown high accuracy and clinical impact of EUS-guided sampling of celiac lymph nodes in oesophageal cancer staging [272–274]. According to the current TNM classification, these are included in the N category [275], with EUS-guided sampling only being useful in selected cases. In addition to EUS-guided sampling of mediastinal lymph nodes, sampling of abdominal lymph nodes in gastric cancer may alter staging classification. Malignant involvement of distant lymph nodes is indicative of metastatic disease and resists the patient to palliative care [117, 118].

**Adrenal glands and liver masses**

EUS-guided sampling of adrenal masses can provide valuable information for the staging of lung cancer and other malignancies. Particularly in lung cancer, 30–80 % of adrenal masses are adenomas [276]. Sampling from the left adrenal gland is viable and safe; sampling from the right adrenal gland has also been reported. The diagnostic yield of EUS-guided sampling ranges from 76–100 %. Further management is altered in approximately 50 % of lung cancer patients [277–289]. EUS and EUS-guided sampling are superior to CT in detecting small liver metastases [290, 291]. The diagnostic yield is reported between 80–98 % with a substantial effect on clinical management [292–298].

**Other metastatic locations and diagnosis of recurrent malignant disease**

EUS and EUS-guided sampling may play a pivotal role in the detection and diagnosis of disease recurrence or late distant spread of gastrointestinal cancer [299]. A high accuracy with clinical impact of EUS-guided sampling has been shown in establishing recurrent malignancy following curative treatment [20, 119–122, 300–304], and metastatic disease, in particular affecting the pancreas [139, 303, 305–307], spleen [308, 309], pelvis [24, 26, 310] and peritoneal space [297, 311–322].

**Recommendation 19**

Combined EUS-guided sampling (EBUS-TBNA and EUS-FNA) is recommended for complete nodal staging of non-small cell lung cancer (LoE 1a, GoR A). Strong consensus (100 %).

**Recommendation 20**

EUS-guided sampling (EBUS-TBNA and EUS-FNA) may be used in mediastinal nodal and metastatic staging of other malignancies (LoE 3a, GoR B). Strong consensus (100 %).

**Recommendation 21**

EUS-guided sampling may be used for the detection of recurrence of malignancies (LoE 3b, GoR C). Strong consensus (100 %).

**Recommendation 22**

When biopsy of suspected metastatic lesions for staging purposes is contemplated, penetration of the primary tumour should be avoided (LoE 5, GoR D). Strong consensus (100 %).

**Recommendation 23**

In cases with suspected distant and/or nodal metastases, algorithmic sampling should be performed beginning with the potentially most advanced metastatic site and following an inverse TNM order (LoE 5, GoR D). Strong consensus (100 %).

**EUS-guided sampling: Needle choice, sampling techniques and other factors influencing diagnostic yield**

### Choice of needle type and diameter


**EUS-guided fine-needle aspiration for cytopathological processing**

Standard aspiration needles were originally designed to obtain cellular material for cytopathological examinations [66, 323, 324]. Cytological yield and diagnostic accuracy, in studies using predominantly 22 G aspiration needles, are reported to be high.
for solid pancreatic lesions and metastatic lymph nodes, satisfactory for biliary mass lesions, but only moderate for gastrointestinal SET and PCL [59, 66, 325, 326]. Currently, the 22 G aspiration needle is most widely used, with increased utilization of 25 G aspiration needles [327–329].

22 G vs. 25 G aspiration needles
Meta-analyses demonstrate slight superiority of the 25 G over the 22 G aspiration needle for EUS-FNA of solid pancreatic lesions [330, 331].

19 G vs. 22 G and 25 G aspiration needles
There was no difference in diagnostic accuracy between the 19 G and the 22 G aspiration needle by intention-to-treat analysis, but the 19 G was superior to the 22 G needle in terms of the amount of cellular material and diagnostic accuracy by per-protocol analysis (following exclusion of 5 technical failures, all with pancreatic head lesions). Further analysis favoured the 19 G aspiration needle for the sampling of lesions within the pancreatic body and tail [332]. A flexible 19 G aspiration needle has been shown to be effective for procuring aspirates from pancreatic head lesions even by the transduodenal route [333–335].

21 G vs. 22 G aspiration needles for EBUS-TBNA
A meta-analysis of 5 studies (n = 1720 patients) did not reveal significant differences in the diagnostic yield, sample adequacy, or the mean number of needle passes between the 21 and 22 G needles during EBUS-TBNA [336].

EUS-guided tissue acquisition for histopathological processing
With increasing requirements of histopathological, immunohistochemical and molecular biological diagnosis [337, 338], three types of “histology needles” have been developed to facilitate acquisition of core cylinders suitable for histopathological examination: trucut needles [50, 51, 339, 340], aspiration needles with a side fenestration (core trap) and reverse bevel technology [53, 55, 341, 342] and aspiration needles with a shark mouth design. Acquisition of tissue suitable for histopathological processing is also possible with standard aspiration needles, not just with “histology needles” [54, 59, 66, 323, 324, 343, 344]. The diagnostic yield for histological material is dependent on the needle diameter.

Recommendation 24
In a referral EUS centre it is advisable to have needles of different size available, and the choice among different needles should be made considering the anatomical location and the type of the target lesion and the preferred mode of processing of the material (LoE 2b, GoR C). Strong consensus (100%).

Recommendation 25
22 G aspiration needles have a high diagnostic yield, low risk of adverse events, and good technical performance, and therefore should be regarded as the current standard for EUS-guided sampling (LoE 2a, GoR B). Strong consensus (100%).

Recommendation 26
25 G aspiration needles are not inferior to 22 G aspiration needles with respect to cytological yield (LoE 1a, GoR A). The use of 25 G needles should be considered in particular for EUS-guided transduodenal sampling of pancreatic head lesions (LoE 2a, GoR C). Strong consensus (100%).

Recommendation 27
Due to a high rate of technical failure, the use of nonflexible 19 G needles is not recommended for transduodenal sampling of pancreatic head masses (LoE 2b, GoR B). Strong consensus (100%).

Factors influencing the yield of EUS-guided sampling
Features of the target lesion
The hypocellular character of the PCL aspirate renders the diagnostic yield and accuracy of EUS-guided sampling of PCL considerably lower than in the case of solid pancreatic lesions. For gastrointestinal SET the diagnostic yield of EUS-guided sampling (specific diagnosis) is approximately 34% [187] to 82% [184], with most studies reporting a yield of 52–63% [179]. Data on the influence of the size and site of solid pancreatic lesions on EUS-FNA accuracy are conflicting [138, 345–348]. The diagnostic accuracy of EUS-FNA for pancreatic cancer is considerably hampered in patients with chronic pancreatitis [349–353]. There are inconsistent results in studies evaluating the influence of biliary stents on EUS-FNA performance characteristics [354, 355].

Sampling technique
Fanning technique
Sampling of all parts of solid lesions and lymph nodes (“fanning technique”) is recommended by the ESGE guidelines on EUS-guided sampling in gastroenterology [54]. According to the results of an RCT, significantly fewer passes are required to establish a diagnosis using this particular technique [356].

Recommendation 28
Fanning technique should be applied in EUS-guided sampling to increase sample adequacy (LoE 2b, GoR C). Strong consensus (100%).

Suction
Traditionally negative suction pressure using a 5 ml or 10 ml syringe is used to facilitate EUS-guided tissue acquisition. Alternatively, the fine-needle capillary sampling technique [357] or slow removal of the stylet (“slow-pull technique”) [358] may be used to draw cells up into the needle lumen. Applying suction to the needle may increase the cellular yield of the aspirate but, at the same time, potentially increases artefacts and contamination by blood. Applying high negative pressure suction has been suggested to facilitate procurement of core tissue in EUS-FNA and EBUS-TBNA [184, 359–363]. An RCT demonstrated that EUS-guided lymph node sampling with suction compared with the fine-needle capillary technique did not improve the likelihood of correct diagnosis, but, due to excessive blood contamination, provided smears of significantly poorer quality [364].
For sampling of pancreatic masses using 22 and 25 G aspiration needles, one RCT favoured EUS-guided fine-needle sampling with 10 ml suction over no suction [365]. In a multicentre RCT the adequacy and accuracy of 22 G EUS-FNA from solid pancreatic lesions were significantly better with 20 ml suction compared with 10 ml suction and no suction [366].

**Recommendation 29**

For aspiration of cysts and fluid collections, negative pressure suction is recommended (LoE 5, GoR D). Strong consensus (100%).

**Recommendation 30**

For sampling of solid pancreatic lesions, negative pressure suction should be considered (LoE 1b, GoR A). Strong consensus (100%).

**Recommendation 31**

In lymph nodes and other highly vascularized solid lesions, sampling without applying suction should be considered (LoE 2b, GoR C). Strong consensus (100%).

**Use of a stylet**

No advantage of using a stylet in terms of specimen quality and diagnostic yield has been demonstrated [367 – 371]. An RCT suggested a lower proportion of adequate samples and a higher probability for blood contamination in needle passes using a stylet compared with needle passes performed without a stylet [367]. A multicentre RCT reported non-inferiority of performing 22 G EUS-FNA of various solid lesions without a stylet compared with using a stylet with respect to the acquisition rate of histological specimens [372].

**Recommendation 32**

Aspiration needles may be used with or without a stylet with the same diagnostic yield (LoE 1b; GoR A). Strong consensus (100%).

**Number of needle passes**

The number of passes is determined based on the results of on-site cytopathological evaluation, should this be available (ROSE)[10] [54, 373, 374]. As an alternative to ROSE-guided sampling, a high number (≥ 7) of needle passes is thought to be a predictor of a high diagnostic sensitivity of EUS-FNA [327].

**Pancreatic lesions**

ROSE study results indicate that diagnosis of a solid pancreatic lesion using standard aspiration needles may require 5 – 7 passes [375 – 377]. When using a 25 G aspiration needle for sampling of a solid pancreatic lesion, 2 – 4 needle passes were adequate for a good diagnostic accuracy [378 – 381]. Using a standard 22 G aspiration needle, 1 – 2 needle passes were sufficient to achieve a high diagnostic yield and accuracy in 92% of cases with solid pancreatic lesions [382]. In the case of PCL with no solid component, a single pass and complete cyst fluid aspiration should be performed to prevent cyst infection [54]. In the case of PCL with a solid component, the diagnostic yield is significantly higher for ≥ 2 needle passes (78%) compared to one needle pass (44%) [383].

**Non-pancreatic lesions**

In the case of lymph nodes, liver metastases and adrenal lesions, a lesser number of needle passes is sufficient to provide a high diagnostic yield. Approximately 3 needle passes were sufficient for EUS-FNA and EBUS-TBNA of lymph nodes [364, 375, 377, 379, 384].

**Recommendation 33**

If ROSE is not available, the number of needle passes should be based on gross visual inspection of the obtained material and the type of target lesion (LoE 2b, GoR C). Strong consensus (100%).

**Targeted sampling**

EFSUMB guidelines recommend the use of contrast-enhanced endoscopic ultrasound (CE-EUS) and of EUS-elastography to facilitate differential diagnosis of solid pancreatic lesions, PCL and lymph nodes [385, 386].

**Lymph nodes**

EUS-elastography, currently strain elastography, has been shown to increase the discriminatory ability of normal EUS criteria, and to improve the specificity of lymph node staging in gastrointestinal malignancy [386, 387]. A meta-analysis calculated a sensitivity of 88% and specificity of 85% with EUS-elastography for differentiating between benign and malignant lymph nodes [388]. EFSUMB guidelines suggest using EUS-elastography for identifying suspicious lymph node and/or harder lymph node regions as targets of EUS-guided sampling [386].

**Solid pancreatic lesions**

The selection of patients for EUS-guided sampling with a high suspicion of diagnoses other than PDAC is of pivotal importance to avoid unnecessary pancreatic head resection with inherent morbidity and mortality [343]. Contrast-enhanced ultrasound (CEUS) and CE-EUS are able to discriminate hypovascular PDAC from other iso- and hypervascular solid pancreatic lesions (non-PDAC) with an accuracy > 85% [385, 389]. A meta-analysis reported the sensitivity and specificity of CE-EUS to diagnose PDAC at 94 and 89%, respectively [390]. When there is a high suspicion of non-PDAC, patients with solid pancreatic mass lesions which are hypervascular or isovascular in comparison with the surrounding pancreatic parenchyma should be referred to pre-therapeutic EUS-guided sampling. Negative results of EUS-guided sampling of solid pancreatic lesions which are hypovascular on CE-EUS should be considered false-negative, initiating repeat sampling or proceeding directly to surgery [391, 392]. An RCT demonstrated that CE-EUS-guided FNA of solid pancreatic lesions is more efficient than conventional EUS-FNA with fewer needle passes required to obtain a diagnostic sample [393].

---

[10] The terms “number of passes” and ROSE are explained in the addendum on terminology (online version only).
EUS-elastography has an high sensitivity, but only a moderate specificity for differentiating malignant from benign solid pancreatic lesions [387]. Meta-analyses report a sensitivity of 95 – 97 % and a specificity of 67 – 76 % [394 – 398]. EFSUMB guidelines recommend that in the case of persisting strong clinical suspicion of pancreatic cancer with inconclusive or negative EUS-guided sampling, a hard focal lesion on elastography and/or a hypovascular lesion on CEUS and or CE-EUS indicates the need for repeat EUS-FNA or referral to surgery [386].

Cystic pancreatic lesions
The presence of epithelial mural nodules, thick walls, and septa has been shown to be highly predictive for malignancy in BD-IPMN [399, 400]. International and European guidelines recommend surgical treatment of BD-IPMN in particular if enhancing nodules or “positive cytology” has been verified [144, 145]. Targeted biopsy of the cyst wall and solid components has a significant incremental diagnostic value over cyst-fluid aspiration alone for the diagnosis of mucinous and malignant cystic neoplasms [383, 401, 402] and is recommended by the ESGE guideline on EUS-guided sampling in gastroenterology [54]. EUS and CE-EUS significantly improve the discrimination and characterization of mural nodules in IPMN in comparison with B-mode EUS and CT [403 – 406], suggesting that CE-EUS may facilitate EUS-guided sampling of solid components in PCL.

Subepithelial gastrointestinal tumours
Differential diagnosis of hypoechoic gastric SETs by EUS and other imaging techniques is difficult [66, 178, 179, 191, 407]. Preliminary findings suggest that CE-EUS can discriminate GIST (hypervascular) from benign lesions (leiomyoma, lipoma: hypovascular) [408].

**Recommendation 34**
Contrast-enhanced EUS and/or EUS-elastography may be used to guide and target EUS-guided sampling of lymph nodes (LoE 2a), solid pancreatic masses (LoE 2a), pancreatic cystic lesions (LoE 2b) and gastrointestinal subepithelial tumours (LoE 3b) (GoR C). Strong consensus (100 %).

**Recommendation 35**
In addition to aspiration of cyst fluid, the cyst wall and solid components, if present, should be sampled in pancreatic cystic lesions (LoE 2b, GoR B). Strong consensus (100 %).

**EUS-guided sampling: Processing and evaluation of specimen**

Techniques for expelling a specimen from the needle
The techniques for expelling a specimen are related to the needle system used. There are three techniques for expelling a specimen from aspiration needles: 1. Air flushing; 2. Saline flushing; 3. Extraction with the stylet. No differences between air flushing and stylet reinsertion with regard to the number of diagnostic specimens, overall accuracy and specimen quality were found in an RCT, but smears were bloodier following stylet use for the expelling of the sample [365].

**Recommendation 36**
Material can be expelled from EUS-aspiration needles using the stylet, by spraying with air on slides, or by flushing the needle with saline (LoE 2b, GoR B). Strong consensus (100 %).

**Recommendation 37**
Controlled release of material onto slides using the stylet is the preferred method despite more blood contamination (LoE 5, GoR D). Strong consensus (100 %).

**Methods for specimen preparation and processing**
Optimizing specimen handling and processing may reduce the frequency of non-diagnostic samples [409, 410]. The handling of the specimen depends on the diagnostic methods used and the final cytopathological evaluation.

**Cytopathology: conventional smears and liquid-based preparations**
For cytological analysis the specimen should be smeared onto slides (smear cytology, SC) or incorporated into special preservation solutions (liquid-based cytology, LBC) for further handling [411, 412]. Prospective comparative trials demonstrated that LBC was less sensitive with material obtained by EUS-guided sampling from lymph nodes and pancreatic lesions compared with traditional SC [413 – 415]. A further RCT suggested that LBC may serve as a complementary preparation technique if blood contamination of smears is abundant [414].

**Histopathology: cell block and core tissue preparation**
In general, histopathological processing including paraffin-embedding, microtome-sectioning, and staining is possible with small coherent tissue cores embedded in a formalin fixative or with CB. A wide variety of ancillary diagnostic techniques (immunohistochemistry, molecular analysis) may be performed on histopathologically processed material [66, 186, 382, 409, 411, 412, 416 – 420].

CB may be prepared from any cell suspension (e.g. liquid aspirates, needle rinses, or specimen in preservative solutions for LB). Pellets of artificially aggregated cells are obtained by using repeated centrifugation and/or special cell capturing gels [410, 412, 417, 421]. Small core particles obtained with aspiration needles or “histology needles” can be directly delivered into formalin solution for fixation followed by standard histopathological processing [53, 217, 409, 410, 422, 423]. Alternatively, core particles may be isolated from samples expelled on glass slides or preservation solutions by the stylet method before further cytopathological processing (”split-up” method) [186, 382, 424].

**Cytopathological evaluation of a specimen**

**Cytopathological vs. histopathological evaluation**
In most cases of PDAC and lymph node metastases, cytopathological evaluation alone is adequate to establish a diagnosis of malignancy. The diagnostic sensitivity of EUS-FNA cytology is highly dependent on the proficiency and experience of the cytopathologist evaluating the specimen [107, 425] and to a lesser extent on the availability of ROSE.

In a number of clinical settings and target lesions, it is tissue architecture, immunohistochemistry and molecular analysis rather...
than cellular features that are essential for accurate pathological assessment [419, 420]. For benign diseases, e.g. autoimmune pancreatitis [426, 427], differential diagnosis of SET (GIST vs. leiomyoma or schwannoma) [52, 181, 189, 191, 428, 429], subtyping of NSCLC and malignant lymphoma [217, 266, 430 – 432], diagnosis of rare tumours [137, 226, 382], grading of neuroendocrine tumours [433–435], molecular profiling of solid tumours [124 – 128, 130, 204 – 209, 409, 436, 437] and differential diagnosis of mediastinal lymph node metastases [52, 226, 438], a core sample is preferred to a cytological aspirate [66].

A complementary approach: combining cytopathological and histopathological assessment

There are two reasonable strategies to achieve high diagnostic accuracy in EUS-guided sampling, without the attendance of a cytopathologist: combining cytopathological and histopathological evaluation [52, 138, 192, 231, 382, 415, 424, 439, 440], or relying on core tissue or CB material for histopathological assessment [53, 55, 217, 333, 409, 422, 423, 427, 430, 441 – 444]. Several studies have shown an incremental yield of combining SC with CB technique or histological core assessment in terms of diagnostic yield and accuracy [138, 192, 231, 382, 415, 439, 440, 445, 446].

Specimen handling for diagnosis of infectious diseases

Suspected infectious disease (e.g. abscesses, tuberculosis or atypical mycobacteriosis) requires specific handling of the aspirate. Microbiological cultures are possible if samples are placed in saline, whereas a polymerase chain reaction (PCR) amplifying mycobacterial DNA requires the specimen placed in formalin [447, 448]. A moderate to high accuracy of SC including Ziehl-Neelsen stain for acid-fast bacteria alone for the diagnosis of tuberculosis and its differentiation from sarcoidosis or histoplasmosis has been reported [447, 449 – 454]. Further studies showed significantly higher sensitivity of PCR vs. microbiological culture and/or SC, and of microbiological culture vs. SC [448, 455 – 457]. In a meta-analysis the overall diagnostic yield of EBUS-TBNA for the diagnosis of mediastinal tuberculous lymphadenitis was 80% with the culture positive rate (54%) being significantly higher than the SC positive rate (33%) [458].

Recommendation 38

The processing of specimen obtained by EUS-guided sampling varies according to the cytopathological or histopathological methods used for diagnosis (LoE 2b, GoR C). Strong consensus (100%).

Recommendation 39

Tissue fragments can be effectively isolated from the whole sample after gross visual examination without impairing the cytopathological result (LoE 2b, GoR B). Strong consensus (100%).

Recommendation 40

Without rapid on-site cytopathological evaluation, the combination of cytopathological and histopathological processing seems to provide the most reliable results (LoE 2b, GoR B). Strong consensus (100%).
Gross visual inspection and ROSE performed by the endosonographer

In the absence of ROSE, gross visual assessment of a sample to assess the adequacy of EUS-guided sampling is possible [482]. Studies show conflicting levels of the ability of endosonographers and trained EUS and cytology assistants to assess slide adequacy and to differentiate malignant and benign specimens [483]. In a prospective evaluation of the visual assessment of core particles obtained with a 19 G ProCore needle, a core length of ≥ 4 mm was an indicator for an adequate histological sample and for a high overall, histological and cytological diagnostic yield [443].

Studies have demonstrated the improved ability of endosonographers, following completion of structured training, to smear and stain slides, to operate a microscope [484], to judge adequacy of a cytological specimen confidently [485], and to differentiate benign and malignant smears with an accuracy of 89 % [486]. ROSE performed by an experienced endosonographer may be reliable, but requires completion of an intensive structured training program.

**Recommendation 44**

Rapid on-site cytopathological assessment does not substantially improve the diagnostic yield of malignancy or generally reduce the number of needle passes. In centres with an adequacy rate < 90 %, ROSE may improve the adequacy of EUS-guided sampling (LoE 2a, GoR C). Strong consensus (100 %).

**Recommendation 45**

Rapid on-site cytopathological assessment may be used to guide the number of needle passes, provide a reliable immediate diagnosis of malignancy, and assess the need for ancillary studies (LoE 2b, GoR C). Strong consensus (100 %).

Reporting and reliability of cytopathology in EUS-guided sampling

**Cytopathological reporting**

In most cytopathological laboratories, the diagnostic categories for EUS-cytology follow a Bethesda-like system: unsatisfactory, benign, atypical, suspicious, and positive for malignancy [412, 490]. Based on a standard nomenclature for FNA [489], the Pananicolau Society of Cytopathology has developed guidelines on standardized terminology and nomenclature for pancreatic-biliary cytopathology, recommending a six-tiered system of diagnostic categories: nondiagnostic, negative, atypical, neoplastic, suspicious, and positive [412]. The category “neoplastic” is unique for pancreatic cytopathology, including benign neoplasms (serous cystadenoma) as well as pre-malignant mucinous cysts, neuroendocrine tumours and solid pseudopapillary neoplasms [490]. The inconclusive and ill-defined diagnostic categories “atypical” and “suspicious for malignancy” are inconsistently conveyed [491 – 493]. Insufficient adherence to standardized nomenclature in cytopathological reporting hampers individual patient management and is a substantial obstacle for the comparison of results between centres and studies [412, 490].

**Reliability of negative (“benign”) results and findings positive for malignancy/neoplasia**

A few studies have analysed the reproducibility of cytopathological diagnoses of specimens obtained by EUS-guided sampling. In most studies a good-to-excellent diagnostic agreement between experienced cytopathologists was documented [425, 494, 495]. For clinical decision-making it is important to understand that there is still a significant risk of malignancy with negative findings in EUS-guided sampling, which is considerably high for PCL, solid pancreatic lesions in patients with underlying chronic pancreatitis, indeterminate biliary strictures, and gastrointestinal SET. The major cause for false-negative diagnoses of EUS-guided sampling is sampling error, whereas interpretative error is rare [66, 165, 325, 349, 350, 491, 492, 496 – 501]. In studies with good reference standards and long follow-up, false-positive findings have been reported for EUS-guided sampling in 1.1 – 5.3 % when only cases with a positive cytopathological result were considered and in 7.8 % if suspicious cytopathology results were included. False-positive rates seem to be higher in luminal compared with extra-luminal (e.g. pancreatic) primary cancer [238, 502, 503]. False-positive findings may result from procedure-related factors, e.g. traversal of a neoplastic area, needle contamination with tumour cells [240, 241], inadvertent aspiration of cancer-cell contaminated luminal fluid [239], or from cytopathological misinterpretation [66, 325, 491, 496 – 498, 501, 502, 504, 505].

**Malignancy risk associated with inconclusive findings**

Studies have evaluated the malignancy risk related with inconclusive diagnostic cytopathological categories for EUS-guided sampling of pancreatic lesions. The suspicious category is associated with an 80 – 96 % risk of neoplastic or malignant final diagnosis, whereas the atypical category carries a markedly variable and significantly lower malignancy risk [492, 493, 506]. Clinical predictors associated with a high likelihood of a neoplastic diagnosis following an atypical cytopathological diagnosis in pancreatic EUS-FNA can be used to adapt management of patients with inconclusive cytopathological diagnoses; ancillary testing, watchful waiting, repeat EUS-guided sampling, alternative diagnostic techniques, or initiation of a specific treatment [501, 507 – 510]. Repeat EUS-guided sampling in patients with high clinical suspicion of malignancy has been shown to yield a conclusive and correct diagnosis in 73 – 84 % of cases with primarily inconclusive cytopathological diagnosis [468, 507, 510 – 512].

**Recommendation 46**

A standardized and validated classification system should be used for cytopathology reporting in EUS-guided sampling (LoE 5, GoR D). Strong consensus (100 %).

**Recommendation 47**

After inconclusive cytopathological results, the use of ancillary studies and/or repeat EUS-guided sampling should be weighed against the clinical background of patient history, clinical and laboratory data, EUS morphology, results of other imaging tests and follow-up (LoE 2b, GoR B). Strong consensus (100 %).

---

11 Terms are explained in the addendum on terminology (long version only).
12 Terms are explained in the addendum on terminology (long version only).
13 Terms are explained in the addendum on terminology (long version only).
Adverse events of EUS-guided interventions and their prevention

General considerations
EUS-guided sampling (including EBUS-TBNA) is a safe diagnostic technique. Severe adverse events are rare. There is no evidence that needle size or needle type affects morbidity of EUS-guided sampling [54, 70, 300, 513]. A systematic review of complications of 51 EUS-FNA studies including 10941 patients describes an overall complication rate of 0.98%. The procedure-related mortality was estimated at 0.02% [514]. Morbidity of EUS-guided therapeutic interventions is considerably higher than EUS-guided sampling, with risk and type of complications depending on the type of procedure [71, 515, 516].

Adverse events

Perforation
The majority of perforations associated with EUS-guided sampling are caused by the passage of the gastrointestinal echoendoscope and not the sampling procedure. Multicentre surveys and studies report perforation rates of 0.03–0.15% [516–520]. The risk of duodenal perforation is higher than oesophageal perforation [70, 516].

Acute pancreatitis
The frequency of acute pancreatitis following EUS-FNA of pancreatic lesions is between 0.19–2.35% [70]. Pancreatitis risk is higher in patients with PCL than in patients with solid pancreatic lesions [70, 514].

Intra- and extraluminal haemorrhage
Severe bleeding following EUS-FNA is a rare event (overall 0.13%) [514]. There are three reports in the literature of fatal bleeding following pancreatic EUS-FNA [70]. There is indirect evidence that EUS-FNA of PCL may cause a higher risk of bleeding compared with EUS-FNA of solid pancreatic lesions [514, 515, 521–523]. Guidelines suggest discontinuing oral anticoagulants, heparin and LMWHs in therapeutic dosages as well as ADP-antagonists before EUS-guided sampling, whereas withdrawal of ASA is recommended only before EUS-FNA of PCL [54, 513, 524–526]. Despite limited evidence for distinct cut-off values, a platelet count < 50 000/ml and an international normalized ratio (INR) > 1.5 are regarded as contraindications to EUS-guided sampling. There is no data regarding needle size, needle type, number of needle passes or other technical factors related to bleeding risk following EUS-guided sampling.

Fever and infection
Bacteremia following upper as well as lower gastrointestinal tract EUS-FNA is a rare event [527–530]. In large series 0.4–1.0% of patients experienced febrile episodes following EUS-FNA for solid pancreatic masses [359, 531, 532]. For endosonographic sampling of mediastinal lesions, studies report an overall frequency of major infectious complications in 0.07% of patients [533]. Serious infectious complications have been reported following EUS-FNA of mediastinal cysts [70, 533], ascites [313], perirectal cysts [26], as well as of PCL and (peri-) pancreatic fluid collections [534]. Despite a lack of convincing evidence, several guidelines recommend peri-interventional antibiotic treatment for EUS-FNA of PCL [54, 513, 524]. Due to potentially catastrophic consequences of mediastinal infection, guidelines and reviews regard EUS-FNA of mediastinal cysts to be contraindicated [54, 70, 513, 524, 533].

Recommendation 50
Transoesophageal EUS-guided sampling of cystic mediastinal lesions should be avoided due to the high risk of infection (LoE 4, GoR C). Strong consensus (100%).

Recommendation 51
Peri-interventional antibiotic treatment is recommended for EUS-guided sampling of cystic lesions and fluid collections as well as in EUS-guided drainage procedures (LoE 5, GoR D). Strong consensus (100%).

Tumour cell seeding and needle track metastasis
Several studies agree that EUS-guided sampling for malignant solid and cystic pancreatic tumours and for cholangiocarcinoma is not a risk factor for the development of peritoneal seeding, tumour recurrence, or decreased survival [535–541]. The risk of peritoneal seeding following biopsy of pancreatic cancer appears to be significantly lower with EUS-FNA compared to percutaneous FNA [542, 543]. However, 11 individual cases of tumour cell seeding caused by EUS-guided sampling of malignant pancreatic neoplasia (n=8, in 4 cases cystic tumours) [544–551] and of lymph node metastases (n=3) [552–554] suggest cautious use of EUS-guided sampling.

Recommendation 52
Tumour cell dissemination along the needle track following EUS-guided sampling is an exceptionally rare event. Pre-operative EUS-guided sampling of pancreatobiliary malignancies is not associated with increased risk of postoperative recurrence, decreased overall survival or decreased cancer-specific survival (LoE 2c, GoR B). Strong consensus (100%).

Miscellaneous complications
There are reports of bile peritonitis following EUS-FNA of the gallbladder or of the liver in patients with biliary obstruction [293, 555, 556], of pneumothorax following transoesophageal EUS-FNA of mediastinal lymph nodes [202], pneumoperitoneum following EUS-FNA of a pancreatic tumour [557] and of pancreatic duct leak caused by EUS-FNA of pancreatic mass lesions [558, 559]. One case of phlegmonous gastritis following EUS-FNA has
been reported [560]. Two cases of a hypertensive crisis induced by EUS-FNA of retroperitoneal paraganglioma or adrenal phaeochromocytoma have been documented [561, 562].

**Risk factors for complications**

There are limited data linking complication rates of EUS-FNA with specific target lesions. Data from a systematic review confirmed that EUS-FNA is exceptionally safe for mediastinal lesions (n = 1310; complication rate: 0.38 %), abdominal masses (n = 381; 0.26 %) and adrenal glands (n = 81; 0 %). Procedure-related morbidity seems to be higher for pancreatic lesions (n = 8246; 1.03 %), liver lesions (n = 344; 2.33 %) and perirectal lesions (n = 193; 2.07 %) [514]. Several studies have shown that performing EUS with/without EUS-guided sampling and ERCP in a single session is safe [563–570]. Observations from high-volume centres suggest that complications are more frequent in the learning phase of the examiners [100, 422, 534].

**Recommendation 53**

EUS-guided sampling of solid lesions is a low-risk procedure. EUS-guided sampling of pancreatic cystic lesions has a higher frequency of adverse events compared to solid pancreatic lesions (LoE 2a, GoR B). Strong consensus (100 %).

**Recommendation 54**

EUS-guided sampling and ERCP may be safely performed in a single session (LoE 2b, GoR B). Strong consensus (100 %).

**Recommendation 55**

Any complications of EUS-guided sampling and therapeutic interventions should be documented in a standardized format in every centre. The incidence of adverse events should be monitored and used as a quality indicator (LoE 5, GoR D). Strong consensus (100 %).

**Affiliations**

1. Department of Internal Medicine, Krankenhaus Märkisch Oderland Strausberg/Wriezen, Germany
2. Department of Internal Medicine 2, Helios Hospital Meiningen GmbH, Meiningen, Germany
3. Gastroenterology Unit, Department of Medical and Surgical Sciences University of Bologna/Hospital of Innola, Italy
4. National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen and Department of Clinical Medicine, University of Bergen, Bergen, Norway
5. Department of Gastroenterology and Endoscopy, Ospedale Maggiore Crema, Italy
6. Department of Medicine and National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway
7. Department of Internal Medicine 2, Caritas Krankenhaus, Bad Mergentheim, Germany
8. Department of Gastroenterology, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Craiova, Romania and Department of Endoscopy, Gastrointestinal Unit, Copenhagen University Hospital Herlev, Denmark
9. GastrOUnit, Department of Surgery, University Hospital Herlev, Copenhagen, Denmark
10. Department of Internal Medicine I, Sana Kliniken, Luebeck, Germany
11. Department of Gastric Surgery, Ultrasound Section, Herlev Hospital, University of Copenhagen, Denmark
12. Department of Gastroenterology, Brandenburg University of Medicine and Health Care, Neuruppin, Germany
13. Department of Radiology, GB Rossi University Hospital, University of Verona, Italy
14. Unit of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Italy
15. Department of Radiology, King’s College Hospital, London, UK
16. Department of Internal Medicine 2, Caritas Krankenhaus, Bad Mergentheim, Germany
17. Sino-German Research Center of Ultrasound in Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

**Acknowledgement**

We acknowledge the advice from Lynne Rudd, EFSUMB general secretary, and the support of the EFSUMB INVUS committee.

**References**

(References online)